A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Inclusion Criteria:

• male or female, ≥ 6years of age;
• who have a diagnosis of allergic asthma ≥ 1 year duration according to American Thoracic Society (ATS) criteria;
• severe persistent allergic asthma who remain symptomatic despite optimal therapy (as per Canadian Asthma Consensus Report (1999));
• Subjects having successfully completed one of the following protocols: CIGE025A011E3, CIGE025A2425, CIGE025AIA05;
• elevated immunoglobin E levels

Exclusion Criteria:

• significant systemic disease
• pregnancy or lactation
• an active lung disease other than allergic asthma (eg: cystic fibrosis, bronchiestasis);
• history of food or drug related severe anaphylactoid or anaphylactic reaction(s);
• current treatment with warfarin (Coumadin®), immunomodulatory therapy (e.g., methotrexate, gold, cyclosporine), or antiplatelet therapy.